Antipsychotics and psilocybin.
39 records in this group. 4 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Overview
Reviewed 2026-10-25Most antipsychotics block 5-HT2A, the serotonin receptor psilocybin acts on (Halman 2024). In small controlled studies in healthy volunteers, risperidone weakened psilocybin's effects in a dose-dependent way, and chlorpromazine reduced pupil dilation and visual distortion (Vollenweider 1998; Keeler 1967). Haloperidol, which mainly blocks dopamine D2 receptors, did not prevent psilocybin's effects: it reduced some, left visual effects unchanged and increased anxiety (Vollenweider 1998). Most other antipsychotics, including quetiapine and aripiprazole, have not been studied with psilocybin.
Stopping a maintenance antipsychotic, especially abruptly, is linked to a higher risk of relapse (Viguera 1997).
Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Rule 2.2(A)(7) lists conditions under which they may, and rule 2.5(A)(2) covers Clinical Facilitators (4 CCR 755-1); the rule text does not state how 2.2(A)(6) and (7) fit together. The rule does not define “antipsychotic medications”, so whether it covers amoxapine, promethazine products or metoclopramide is unsettled; those records sit in other classes and show Colorado as Unsettled. No Oregon provision names the class, and New Mexico's rules are not final.
Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.
- Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
- Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998;9:3897–3902.
- Keeler MH. Chlorpromazine antagonism of psilocybin effect. Int J Neuropsychiatry 1967;3:66–71.
- Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54(1):49–55.
- 4 CCR 755-1, official Secretary of State text, effective 03/30/2025; Rule 5.4 emergency rule effective 12/05/2025 (official Colorado rule text)
Also searched as antipsychotic · neuroleptic
01 What the evidence covers
Best evidence available per medication| 3 | Controlled trial |
| 1 | Other psychedelic Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text |
| 35 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZPostoperative nausea and vomiting (prevention and treatment)
This antipsychotic barely acts at the receptor psilocybin works through, so weakening of psilocybin is uncertain. Stopping it suddenly after regular use can cause relapse.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
- Aripiprazole · Abilify, Abilify Maintena, Aristada, Abilify Asimtufii, OpipzaEvidence: No psilocybin data
Schizophrenia; Bipolar I disorder (manic and mixed episodes)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar I disorder (manic or mixed episodes, alone or with lithium or valproate, and maintenance)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (add-on to antidepressants); Schizophrenia
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar I disorder (manic or mixed episodes)
It also blocks the receptor psilocybin works through, though more weakly, so it may weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia and other psychotic disorders; Mania in bipolar disorder
In a small study, 50 mg given 2 hours earlier reduced psilocybin's pupil dilation and visual distortion. Also, it sedates and can lower blood pressure.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Treatment-resistant schizophrenia; Reducing suicidal behavior in schizophrenia or schizoaffective disorder
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can cause low blood pressure, sedation and seizures.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it is sedating and can affect heart rhythm.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
- FluphenazineEvidence: No psilocybin data
Psychotic disorders; Schizophrenia requiring long-term injectable treatment (decanoate)
Not studied with psilocybin. In a small study, haloperidol, a similar dopamine blocker, did not prevent psilocybin's effects but increased anxiety.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotic disorders; Tourette's disorder (tics)
In a controlled study, it reduced psilocybin's sense of boundlessness and detachment but increased anxiety; visual effects were unchanged.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia in adults; Manic or mixed episodes of bipolar I disorder in adults
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause relapse.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Agitation in schizophrenia or bipolar I disorder (inhaled form, adults)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can make seizures more likely.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar depression (bipolar I or II)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar depression (bipolar I)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia in adults; Manic or mixed episodes of bipolar I disorder in adults
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause relapse.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
- MolindoneEvidence: No psilocybin data
Schizophrenia
A related drug did not block psilocybin's effects in a small study but raised anxiety; molindone is expected to act similarly.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar I disorder (manic or mixed episodes and maintenance)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can lower blood pressure on standing.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Bipolar depression (bipolar I); Treatment-resistant depression
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar I disorder (manic or mixed episodes and maintenance)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can trigger severe opioid withdrawal.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
- Paliperidone · Invega, Invega Sustenna, Invega Trinza, Invega Hafyera, ErzofriEvidence: No psilocybin data
Schizophrenia; Schizoaffective disorder
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, injected forms last for months.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause relapse.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
- PerphenazineEvidence: No psilocybin data
Schizophrenia; Severe nausea and vomiting (adults)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, the combination product with amitriptyline adds that antidepressant's effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Hallucinations and delusions in Parkinson's disease psychosis
It directly blocks the receptor psilocybin works through, so it is expected to cancel psilocybin's effects. Also, it can cause heart-rhythm (QT) effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Motor and vocal tics of Tourette's disorder (after standard treatment)
Not studied with psilocybin; haloperidol, a similar dopamine blocker, did not prevent psilocybin's effects but increased anxiety. Also, pimozide can affect heart rhythm (QT).
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, the injection stays in the body for weeks.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Severe nausea and vomiting; Schizophrenia
Whether it weakens psilocybin's effects is uncertain; a similar dopamine blocker, haloperidol, increased anxiety with psilocybin. Also, it is sedating.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar I disorder (manic episodes)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar I disorder (acute manic or mixed episodes)
In a controlled study, it weakened psilocybin's effects, more at the higher dose. Also, long-acting injections keep it in the body.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can cause marked heart-rhythm (QT) effects.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It mainly blocks dopamine, not psilocybin's receptor, so any weakening of psilocybin is possible but unstudied. Also, it can affect heart rhythm and seizure risk.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia not responding to other antipsychotics
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it strongly affects heart rhythm (boxed warning).
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia
Whether it weakens psilocybin is uncertain; a related drug, haloperidol, increased anxiety with psilocybin. Also, it causes sedation and low blood pressure.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
- TrifluoperazineEvidence: No psilocybin data
Schizophrenia; Generalized anxiety (short-term, non-psychotic)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can cause low blood pressure and sedation.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia (adults)
It does not block psilocybin's receptor, and its effect on psilocybin is unknown. Also, it often causes nausea, vomiting and faster heart rate.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar I disorder (manic or mixed episodes and maintenance)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can affect heart rhythm and cause sleepiness.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Also, it can cause sleepiness and affect heart rhythm.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
Its serotonin-blocking action may weaken psilocybin. Also, it can affect heart rhythm and cause sedation; the depot injection persists for weeks.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 33 | Lowers blood pressure or causes orthostasis |
| 33 | Sedating or CNS depressant |
| 32 | Lowers seizure threshold or carries seizure risk |
| 31 | Blocks 5-HT2A (may blunt effects) |
| 21 | QT-prolonging |
| 16 | Anticholinergic |
| 16 | Withdrawal or rebound if stopped abruptly |
| 7 | Psychiatric reactions |
| 1 | Dehydration or electrolyte risk |
| 1 | Opioid blocker |
| 1 | Raises blood pressure or heart rate |
| 1 | Serotonergic |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governs39 of 39 named by a provision.
Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” and does not limit this by indication or dose. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).
Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” and does not limit this by indication or dose; prochlorperazine is a phenothiazine antipsychotic FDA-approved for schizophrenia as well as severe nausea and vomiting. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).
Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” without defining the term or limiting it by indication, so it is shown here as covering this medication; the regulator has not addressed this. Xanomeline–trospium is FDA-approved for schizophrenia, but it acts on muscarinic receptors and does not block dopamine receptors, the action other antipsychotics share. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRecords reviewed 2026-10-14 to 2026-11-02. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z